Skip to contentH
Heron Therapeutics, Inc.
H
HRTXHeron Therapeutics, Inc. Q4 2016 · 10-K
Revenue$1.28M$1.28Mno prior Q4 2015 on file Net Income-$47.96M-$47.96MN/M vs Q4 2015 EPS Diluted-$1.22-$1.22N/M vs Q4 2015 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Heron Therapeutics, Inc. · CIK 818033 · Engraved from SEC EDGAR
derived
Operating Cash Flowderived-$38,521,000N/M Free Cash Flowderived-$39,210,000N/M Margins · derivedGross margin97.3%
Operating margin-3659.3%
Net margin-3750.0%
ended Dec 31, 2016 · filed Feb 23, 2017 · 54 d after period end